Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2020
Venclyxto in combination with obinutuzumab is included in the high-cost protection with limitation
28 August 2020 - Venclyxto (venetoclax) is already included in the high-cost protection with limited subsidy. ...
Posted by Michael Wonder on 03 Sep 2020
Tolak is included in the high-cost protection
2 September 2020 - Tolak, a topical treatment for adults with non-hyperkeratotic and non-hypertrophic actinic keratosis (Olsen grade I and II) ...
Posted by Michael Wonder on 02 Sep 2020
Namuscla is granted a temporary subsidy
1 September 2020 - TLV has decided that Namuscla 167 mg capsules will be included in the high-cost protection until ...
Posted by Michael Wonder on 01 Sep 2020
Emgality is included in the high-cost protection with limitation
1 September 2020 - Emgality (galcanezumab), which is a preventive drug treatment for migraines, is included in the high-cost protection with ...
Posted by Michael Wonder on 01 Sep 2020
New formulation of Entyvio is included in the high-cost protection with limitation
1 September 2020 - Entyvio (vedolizumab) in the new dosage form of a solution for subcutaneous injection is included in the ...
Posted by Michael Wonder on 31 Aug 2020
A new biosimilar to NovoRapid is included in the high-cost protection
28 August 2020 - Insulin aspart Sanofi (insulin aspart) solution for injection for the treatment of diabetes is included in ...
Posted by Michael Wonder on 29 Aug 2020
Rybelsus is included in the high-cost protection with restriction
28 August 2020 - Rybelsus (semaglutide) is intended for the treatment of adults with type 2 diabetes in adults as the ...
Posted by Michael Wonder on 13 Jul 2020
EUnetHTA is extended for one year and focuses on COVID-19
9 July 2020 - The European project EUnetHTA, in which TLV, SBU and the Swedish Medicines Agency are Swedish partners, ...
Posted by Michael Wonder on 08 Jul 2020
TLV is reviewing the subsidy of SGLT-2 inhibitors
8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors. ...
Posted by Michael Wonder on 30 Jun 2020
FINOSE - Nordic cooperation extended to promote patients' access to medicines
30 June 2020 - The latest FINOSE report is used as the basis of all the five Nordic countries in ...
Posted by Michael Wonder on 29 Jun 2020
Health economic assessment of Ondexxya in life-threatening or uncontrolled bleeding
26 June 2020 - TLV has developed a health economic assessment for the regions of the drug Ondexxya (andexanet alfa). ...
Posted by Michael Wonder on 28 Jun 2020
The reimbursement for medicines is expected to decrease by SEK 185 million in 2020
26 June 2020 - Pharmaceutical companies will pay SEK 2.9 billion in reimbursement for medicines covered by side agreements between ...
Posted by Michael Wonder on 18 Jun 2020
TLV has decided to change the subsidy status for certain drugs
18 June 2020 - TLV has reviewed the subsidy status for drugs that are included in the Swedish Medicines Agency's ...
Posted by Michael Wonder on 11 Jun 2020
Health economic assessment of Waylivra in familial chylomicronaemia
11 June 2020 - TLV has made a health economic assessment to the regions of the drug Waylivra (volansorsen). ...
Posted by Michael Wonder on 09 Jun 2020
Desloratadine new exchange groups
9 June 2020 - As of 1 July, desloratadine will be included as exchange group on the list of products ...